EU Approves Expanded Use of ABBV's Tepkinly in Follicular LymphomaZacks Investment Research • 07/07/26
3 High-Yield Dividend Stocks to Buy and Hold Forever (Hint: AbbVie Makes the List)The Motley Fool • 07/07/26
AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular LymphomaPRNewsWire • 07/06/26
J&J or AbbVie: Which Stock Deserves a Place in Your Portfolio Now?Zacks Investment Research • 07/02/26
What Sparked the $43B Jump in AbbVie's Market Cap in the Past Week?Zacks Investment Research • 06/30/26
Merck, AbbVie probed by US lawmakers over China clinical trials: reportProactive Investors • 06/30/26
Genmab/AbbVie Lymphoma Trial Meets Main Goal, Analyst Eyes Bigger Market OpportunityBenzinga • 06/30/26
AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell LymphomaPRNewsWire • 06/29/26
ABBV Gets CHMP Nod for Rinvoq in Two Different Autoimmune DiseasesZacks Investment Research • 06/29/26
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia AreataPRNewsWire • 06/29/26
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental VitiligoPRNewsWire • 06/29/26
SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic DiseasePRNewsWire • 06/26/26